WNT16 is Robustly Increased by Oncostatin M in Mouse Calvarial Osteoblasts and Acts as a Negative Feedback Regulator of Osteoclast Formation Induced by Oncostatin M

References

• Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–523. doi:10.1016/S0092-8674(01)00571-2
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–1521. doi:10.1056/NEJMoa013444
   PubMed Web of Science ®Google Scholar
• Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11–19. doi:10.1086/338450
   PubMed Web of Science ®Google Scholar
• Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149(6):1192–1205. doi:10.1016/j.cell.2012.05.012
   PubMed Web of Science ®Google Scholar
• Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537–543. doi:10.1093/hmg/10.5.537
   PubMed Web of Science ®Google Scholar
• Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91–97. doi:10.1136/jmg.39.2.91
   PubMed Web of Science ®Google Scholar
• Laine CM, Joeng KS, Campeau PM, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med. 2013;368(19):1809–1816. doi:10.1056/NEJMoa1215458
   PubMed Web of Science ®Google Scholar
• Kiper POS, Saito H, Gori F, et al. Cortical-bone fragility–insights from sfrp4 deficiency in pyle’s disease. N Engl J Med. 2016;374(26):2553–2562. doi:10.1056/NEJMoa1509342
   PubMed Web of Science ®Google Scholar
• Moverare-Skrtic S, Henning P, Liu X, et al. Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat Med. 2014;20(11):1279–1288. doi:10.1038/nm.3654
   PubMed Web of Science ®Google Scholar
• Gori F, Lerner U, Ohlsson C, Baron R. A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures. Bonekey Rep. 2015;4:669. doi:10.1038/bonekey.2015.36
   PubMedGoogle Scholar
• Ohlsson C, Henning P, Nilsson KH, et al. Inducible Wnt16 inactivation: WNT16 regulates cortical bone thickness in adult mice. J Endocrinol. 2018;237(2):113–122. doi:10.1530/JOE-18-0020
   PubMed Web of Science ®Google Scholar
• Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–192. doi:10.1038/nm.3074
   PubMed Web of Science ®Google Scholar
• Lerner UH, The OC. WNT system: background and its role in bone. J Intern Med. 2015;277(6):630–649. doi:10.1111/joim.12368
   PubMed Web of Science ®Google Scholar
• Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med. 2012;18(3):405–412. doi:10.1038/nm.2653
   PubMed Web of Science ®Google Scholar
• Chen K, Ng PY, Chen R, et al. Sfrp4 repression of the Ror2/Jnk cascade in osteoclasts protects cortical bone from excessive endosteal resorption. Proc Natl Acad Sci U S A. 2019;116(28):14138–14143. doi:10.1073/pnas.1900881116
   PubMed Web of Science ®Google Scholar
• Albers J, Keller J, Baranowsky A, et al. Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol. 2013;200(4):537–549. doi:10.1083/jcb.201207142
   PubMed Web of Science ®Google Scholar
• Weivoda MM, Ruan M, Hachfeld CM, et al. Wnt signaling inhibits osteoclast differentiation by activating canonical and noncanonical cAMP/PKA pathways. J Bone Miner Res. 2016;31(1):65–75. doi:10.1002/jbmr.2599
   PubMed Web of Science ®Google Scholar
• Yu B, Chang J, Liu Y, et al. Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-kappaB. Nat Med. 2014;20(9):1009–1017. doi:10.1038/nm.3586
   PubMed Web of Science ®Google Scholar
• Wang F, Tarkkonen K, Nieminen-Pihala V, et al. Mesenchymal cell-derived juxtacrine wnt1 signaling regulates osteoblast activity and osteoclast differentiation. J Bone Miner Res. 201934(6):1129–1142. doi:10.1002/jbmr.3680.
   Web of Science ®Google Scholar
• Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44(5):491–501. doi:10.1038/ng.2249
   PubMed Web of Science ®Google Scholar
• Zheng HF, Tobias JH, Duncan E, et al. WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet. 2012;8(7):e1002745. doi:10.1371/journal.pgen.1002745
   PubMed Web of Science ®Google Scholar
• Moverare-Skrtic S, Wu J, Henning P, et al. The bone-sparing effects of estrogen and WNT16 are independent of each other. Proc Natl Acad Sci U S A. 2015;112(48):14972–14977. doi:10.1073/pnas.1520408112
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Nilsson KH, Henning P, et al. WNT16 overexpression partly protects against glucocorticoid-induced bone loss. Am J Physiol Endocrinol Metab. 2018;314(6):E597–E604. doi:10.1152/ajpendo.00292.2017
   PubMed Web of Science ®Google Scholar
• Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656–664. doi:10.1038/nrrheum.2012.153
   PubMed Web of Science ®Google Scholar
• Souza PP, Lerner UH. The role of cytokines in inflammatory bone loss. Immunol Invest. 2013;42(7):555–622.
   PubMed Web of Science ®Google Scholar
• Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease. BMB Rep. 2010;43(8):513–523. doi:10.5483/BMBRep.2010.43.8.513
   PubMed Web of Science ®Google Scholar
• Lerner UH. Role of interleukins on physiological and pathological bone resorption and bone formation. II. Effects by cytokines in the IL-6 and IL-10 families. In: Encyclopedia of Bone. Vol. 2. Oxford: Academic Press; 2020:67–87.
   Google Scholar
• Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002;169(6):3353–3362. doi:10.4049/jimmunol.169.6.3353
   PubMed Web of Science ®Google Scholar
• Persson E, Souza PPC, Floriano-Marcelino T, Conaway HH, Henning P, Lerner UH. Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor. Front Immunol. 2019;10:1164. doi:10.3389/fimmu.2019.01164
   PubMed Web of Science ®Google Scholar
• Zarling JM, Shoyab M, Marquardt H, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A. 1986;83(24):9739–9743. doi:10.1073/pnas.83.24.9739
   PubMed Web of Science ®Google Scholar
• Walker EC, McGregor NE, Poulton IJ, et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 2010;120(2):582–592. doi:10.1172/JCI40568
   PubMed Web of Science ®Google Scholar
• Lisignoli G, Piacentini A, Toneguzzi S, et al. Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL-11, leukaemia inhibitory factor and oncostatin M. Clin Exp Immunol. 2000;119(2):346–353. doi:10.1046/j.1365-2249.2000.01114.x
   PubMed Web of Science ®Google Scholar
• Pradeep AR, Garima STM, Garima G, Raju A. Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. Biomarkers. 2010;15(3):277–282. doi:10.3109/13547500903573209
   PubMed Web of Science ®Google Scholar
• West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579–589. doi:10.1038/nm.4307
   PubMed Web of Science ®Google Scholar
• Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol. 2008;181(10):7243–7253. doi:10.4049/jimmunol.181.10.7243
   PubMed Web of Science ®Google Scholar
• Torossian F, Guerton B, Anginot A, et al. Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. JCI Insight. 2017;2(21). doi:10.1172/jci.insight.96034
   PubMed Web of Science ®Google Scholar
• Blumenthal A, Ehlers S, Lauber J, et al. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood. 2006;108(3):965–973. doi:10.1182/blood-2005-12-5046
   PubMed Web of Science ®Google Scholar
• Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 2008;28(3):504–510. doi:10.1161/ATVBAHA.107.157438
   PubMed Web of Science ®Google Scholar
• Manicassamy S, Reizis B, Ravindran R, et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science. 2010;329(5993):849–853. doi:10.1126/science.1188510
   PubMed Web of Science ®Google Scholar
• Neumann J, Schaale K, Farhat K, et al. Frizzled1 is a marker of inflammatory macrophages, and its ligand Wnt3a is involved in reprogramming Mycobacterium tuberculosis-infected macrophages. FASEB J. 2010;24(11):4599–4612. doi:10.1096/fj.10-160994
   PubMed Web of Science ®Google Scholar
• Ouchi N, Higuchi A, Ohashi K, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010;329(5990):454–457. doi:10.1126/science.1188280
   PubMed Web of Science ®Google Scholar
• Irvine KM, Clouston AD, Gadd VL, et al. Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury. Fibrogenesis Tissue Repair. 2015;8(1):19. doi:10.1186/s13069-015-0036-7
   PubMedGoogle Scholar
• Gatica-Andrades M, Vagenas D, Kling J, et al. WNT ligands contribute to the immune response during septic shock and amplify endotoxemia-driven inflammation in mice. Blood Adv. 2017;1(16):1274–1286. doi:10.1182/bloodadvances.2017006163
   PubMed Web of Science ®Google Scholar
• Dell’accio F, De Bari C, Eltawil NM, Vanhummelen P, Pitzalis C. Identification of the molecular response of articular cartilage to injury, by microarray screening: wnt-16 expression and signaling after injury and in osteoarthritis. Arthritis Rheum. 2008;58(5):1410–1421. doi:10.1002/art.23444
   PubMedGoogle Scholar
• Nalesso G, Thomas BL, Sherwood JC, et al. WNT16 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis. Ann Rheum Dis. 2017;76(1):218–226. doi:10.1136/annrheumdis-2015-208577
   PubMed Web of Science ®Google Scholar
• Tong W, Zeng Y, Chow DHK, et al. Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade. Ann Rheum Dis. 2019;78(4):551–561. doi:10.1136/annrheumdis-2018-214200
   PubMed Web of Science ®Google Scholar
• Tornqvist AE, Grahnemo L, Nilsson KH, Funck-Brentano T, Ohlsson C, Moverare-Skrtic S. Wnt16 overexpression in osteoblasts increases the subchondral bone mass but has no impact on osteoarthritis in young adult female mice. Calcif Tissue Int. 2020;107(1):31–40. doi:10.1007/s00223-020-00682-7
   PubMed Web of Science ®Google Scholar
• Liu X, Li X, Hua B, Yang X, Zheng J, Liu S. WNT16 is upregulated early in mouse TMJ osteoarthritis and protects fibrochondrocytes against IL-1beta induced inflammatory response by regulation of RUNX2/MMP13 cascade. Bone. 2021;143:115793. doi:10.1016/j.bone.2020.115793
   PubMed Web of Science ®Google Scholar
• Granholm S, Henning P, Lindholm C, Lerner UH. Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2. Bone. 2013;52(1):83–92. doi:10.1016/j.bone.2012.09.019
   PubMed Web of Science ®Google Scholar
• Granholm S, Lundberg P, Lerner UH. Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms. J Endocrinol. 2007;195(3):415–427. doi:10.1677/JOE-07-0338
   PubMed Web of Science ®Google Scholar
• Lassen NE, Andersen TL, Ploen GG, et al. Coupling of bone resorption and formation in real time: new knowledge gained from human haversian BMUs. J Bone Miner Res. 2017;32(7):1395–1405. doi:10.1002/jbmr.3091
   PubMed Web of Science ®Google Scholar
• Tikhonova AN, Dolgalev I, Hu H, et al. The bone marrow microenvironment at single-cell resolution. Nature. 2019;569(7755):222–228. doi:10.1038/s41586-019-1104-8
   PubMed Web of Science ®Google Scholar
• Matsushita Y, Nagata M, Kozloff KM, et al. A Wnt-mediated transformation of the bone marrow stromal cell identity orchestrates skeletal regeneration. Nat Commun. 2020;11(1):332. doi:10.1038/s41467-019-14029-w
   PubMed Web of Science ®Google Scholar
• Yahara Y, Barrientos T, Tang YJ, et al. Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair. Nat Cell Biol. 2020;22(1):49–59. doi:10.1038/s41556-019-0437-8
   PubMed Web of Science ®Google Scholar
• Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26(5):545–558. doi:10.1016/j.cytogfr.2015.07.006
   PubMed Web of Science ®Google Scholar
• Richards CD. The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm. 2013;2013:512103. doi:10.1155/2013/512103
   PubMedGoogle Scholar
• Hermanns HM, Radtke S, Haan C, et al. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. J Immunol. 1999;163(12):6651–6658.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Dahmen H, Grimm C, et al. The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction. J Immunol. 2000;164(2):848–854. doi:10.4049/jimmunol.164.2.848
   PubMed Web of Science ®Google Scholar
• Hintzen C, Evers C, Lippok BE, et al. Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation. J Biol Chem. 2008;283(28):19465–19477. doi:10.1074/jbc.M710157200
   PubMed Web of Science ®Google Scholar
• Anhuf D, Weissenbach M, Schmitz J, et al. Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation. J Immunol. 2000;165(5):2535–2543. doi:10.4049/jimmunol.165.5.2535
   PubMed Web of Science ®Google Scholar
• Neel BG, Gu H, The PL. ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28(6):284–293. doi:10.1016/S0968-0004(03)00091-4
   PubMed Web of Science ®Google Scholar
• Hermanns HM, Radtke S, Schaper F, Heinrich PC, Behrmann I. Non-redundant signal transduction of interleukin-6-type cytokines. The adapter protein Shc is specifically recruited to rhe oncostatin M receptor. J Biol Chem. 2000;275(52):40742–40748. doi:10.1074/jbc.M005408200
   PubMed Web of Science ®Google Scholar
• Wang Y, Robledo O, Kinzie E, et al. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem. 2000;275(33):25273–25285. doi:10.1074/jbc.M002296200
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem. 1999;274(27):19301–19308.
   PubMed Web of Science ®Google Scholar
• Udagawa N, Takahashi N, Katagiri T, et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med. 1995;182(5):1461–1468. doi:10.1084/jem.182.5.1461
   PubMed Web of Science ®Google Scholar
• McGregor NE, Murat M, Elango J, et al. IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis. J Biol Chem. 2019;294(19):7850–7863. doi:10.1074/jbc.RA119.008074
   PubMed Web of Science ®Google Scholar
• Jilka RL. Parathyroid hormone-stimulated development of osteoclasts in cultures of cells from neonatal murine calvaria. Bone. 1986;7(1):29–40. doi:10.1016/8756-3282(86)90149-3
   PubMed Web of Science ®Google Scholar
• Walker EC, Johnson RW, Hu Y, et al. Murine oncostatin M acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass. J Biol Chem. 2016;291(41):21703–21716. doi:10.1074/jbc.M116.748483
   PubMed Web of Science ®Google Scholar
• Wills MK, Jones N. Teaching an old dogma new tricks: twenty years of Shc adaptor signalling. Biochem J. 2012;447(1):1–16. doi:10.1042/BJ20120769
   PubMedGoogle Scholar
• Wergedal JE, Kesavan C, Brommage R, Das S, Mohan S. Role of WNT16 in the regulation of periosteal bone formation in female mice. Endocrinology. 2015;156(3):1023–1032. doi:10.1210/en.2014-1702
   PubMed Web of Science ®Google Scholar
• Guihard P, Boutet MA, Brounais-le Royer B, et al. Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury. Am J Pathol. 2015;185(3):765–775. doi:10.1016/j.ajpath.2014.11.008
   PubMed Web of Science ®Google Scholar